Answers are grounded in this paper and cite their sources.
Narrative review details oxidative stress pathways across the fatty liver disease spectrum, highlighting antioxidant targets for therapy.
Nonalcoholic fatty liver disease (NAFLD) is currently the most common liver disease in the world. It encompasses a histological spectrum, ranging from simple, nonprogressive steatosis to nonalcoholic steatohepatitis (NASH), which may progress to cirrhosis and hepatocellular carcinoma. While liver-related complications are confined to NASH, emerging evidence suggests both simple steatosis and NASH predispose to type 2 diabetes and cardiovascular disease. The pathogenesis of NAFLD is currently unknown, but accumulating data suggest that oxidative stress and altered redox balance play a crucial role in the pathogenesis of steatosis, steatohepatitis, and fibrosis. We will examine intracellular mechanisms, including mitochondrial dysfunction and impaired oxidative free fatty acid metabolism, leading to reactive oxygen species generation; additionally, the potential pathogenetic role of extracellular sources of reactive oxygen species in NAFLD, including increased myeloperoxidase activity and oxidized low density lipoprotein accumulation, will be reviewed. We will discuss how these mechanisms converge to determine the whole pathophysiological spectrum of NAFLD, including hepatocyte triglyceride accumulation, hepatocyte apoptosis, hepatic inflammation, hepatic stellate cell activation, and fibrogenesis. Finally, available animal and human data on treatment opportunities with older and newer antioxidant will be presented. Antioxid. Redox Signal. 15, 1325–1365. I. Introduction: Importance of Nonalcoholic Fatty Liver Disease and of Altered Redox Balance for the APathogenesis of Nonalcoholic Fatty Liver Disease A. Summary II. Free Fatty Acid Oxidation as a Source of ROS A. Overview of hepatic fatty acid oxidative pathways and their altered homeostasis in NAFLD B. Mitochondrial FA oxidation: β-oxidation C. Peroxisomal β-oxidation D. Microsomal ω-oxidation of FAs: role of cytochrome P450 enzymes in the pathogenesis of NASH E. Summary III. Lysosomal-Mitochondrial Axis as a Mediator of FFA Hepatic Lipotoxicity in NASH A. Summary IV. Modulation of Mitochondrial Function and Potential Therapeutic Implications for NAFLD A. Inhibition of ACC system B. Modulation of PPAR-γ coactivator 1α gene activity C. Modulation of PPAR-α activity D. Modulation of PPAR-γ activity E. Modulation of PPAR-δ activity F. Summary V. Adipokines in NAFLD A. Leptin B. Tumor necrosis factor-α C. Resistin D. Adiponectin E. Retinol binding protein 4 F. Renin-angiotensin system G. Interleukin-6 H. Summary VI. Mechanisms of ROS-Induced Liver Injury in NAFLD A. Inhibition of very low-density lipoprotein secretion from hepatocytes B. JNK pathway activation C. TNF-α pathway activation D. ER stress in the pathogenesis of NASH E. Role of TG cellular stores in mitochondrial dysfunction and liver injury in NASH 1. ER stress and FFA overflow to the liver 2. ER stress and hepatic de novo lipogenesis 3. ER stress and hepatic VLDL secretion F. Role of free cholesterol in mitochondrial dysfunction and liver injury in NASH G. Summary VII. UCPs and Mitochondrial Dysfunction A. Summary VIII. Mitochondrial Dysfunction as a Link Between Maternal Fat Overnutrition and NASH in Adult Offspring A. Summary IX. Myeloperoxidase Involvement in Liver Injury in NASH A. Summary X. Nitrosative Stress in the Pathogenesis of NASH A. Summary XI. Oxidized LDL and Hepatic Fibrogenesis in NAFLD A. Summary XII. Antioxidant Systems in NAFLD A. Vitamin E B. Coenzyme Q10 (ubiquinone) C. Mitochondrial MnSOD D. Mitochondrial glutathione peroxidase E. Heme oxygenase F. Summary XIII. Newer Antioxidants with Potential Therapeutic Applications in NASH A. Silibinin/silymarin B. Curcumin C. Resveratrol D. Viusid E. Summary XIV.
No takes yet. Share an insight, caveat, or question.
Gambino et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: